---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-069169"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T05:17:49.119110+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ArriVent projects topline phase 3 FURVENT data for firmonertinib in early 2026

## Summary
- Topline firmonertinib monotherapy data from pivotal Phase 3 FURVENT study in 1L NSCLC EGFR exon20ins projected early 2026.
- Primary endpoint is progression-free survival by blinded independent central review per RECIST 1.1.
- Enrollment in the global FURVENT study completed in Q1 2025.
- Firmonertinib previously received FDA Breakthrough Therapy Designation for this patient population.

## SEC filing metadata
- accession: 0001104659-25-069169
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465925069169/0001104659-25-069169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465925069169/tm2521271d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-069169
- JSON: https://secwatch.observer/filing/0001104659-25-069169.json
- Plain text: https://secwatch.observer/filing/0001104659-25-069169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.